跳至主要内容
临床试验/JPRN-jRCT1031230137
JPRN-jRCT1031230137招募中4 期

Randomized Controlled Trial to Evaluate the Prophylactic Effect of Mpox with LC16, a Dried Cell Culture Vaccine for Smallpox

Mugen Ujiie0 个研究点目标入组 5,000 人开始时间: 2023年6月15日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
5,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 18age old 至 ot applicable(—)
性别
All

入选标准

  • (1) Persons who have given written consent to participate in the research
  • (2) Persons who are 18 years of age or older at the time consent is obtained
  • (3) Persons at high risk of contracting Mpox*
  • *Persons at high risk of contracting Mpox are defined as those who meet one of the following conditions:
  • A) Those who are already known to be infected with HIV, are receiving continuous anti-HIV therapy, and have a confirmed CD4-positive cell count of 200/microL or higher within 6 months prior to study enrollment.
  • B) HIV screening test negative within four months prior to study enrollment, and who meet one of the following conditions
  • a) Men who have sex with men (regardless of sexuality, such as gay, bisexual, transgender, etc.) and have a history of bacterial sexually transmitted disease (syphilis, gonorrheal infection, chlamydia infection, Mycoplasma genitalium infection, etc) within the past year, or have participated in group sex within the past year, or have two or more sexual partners within the past year.
  • b) Is taking pre-exposure prophylaxis (PrEP) for HIV infection.

排除标准

  • 1) Persons with a history of Mpox
  • 2) Persons with a history of taking smallpox vaccine after 2022
  • 3) Persons with a moderate or greater risk* of contact within 14 days with a confirmed Mpox patient
  • 4) Persons who are immunocompromised (e.g., those on oral / intravenous corticosteroids, cyclosporine, tacrolimus, azathioprine, other immunosuppressive drugs, or biologics. HIV-infected patients who are receiving continuous anti-HIV therapy and whose CD4-positive cell count is confirmed to be 200/microL or higher within 6 months prior to study enrollment will be excluded from this condition.)
  • 5) Persons with known history of anaphylaxis caused by a component of the smallpox vaccine.
  • 6) Women who are or who may be pregnant.
  • 7) Persons deemed inappropriate for inclusion in the study by the principal investigator.
  • * Contact history within 1 meter, contact with normal skin, contact with family members who live or sleep with the patient, contact with mucous membranes including wounds, etc.

研究者

发起方
Mugen Ujiie

相似试验